Keeping tracking on track
Our best practice approach to tracking studies.
Tracking is essential to ensuring a successful brand. But as markets continuously change, it’s imperative that your tracker keeps pace and continues to provide the answers you need throughout the brand’s lifecycle. Our latest infographic outlines Research Partnership’s best practice approach to tracking studies.
Interactive infographic: LATAM
An overview of the six most-commonly researched, largest pharma markets in Latin America
The LATAM region's largest markets of Argentina, Brazil, Chile, Colombia, Mexico and Venezuela, is home to more than 460 million people and is a key global growth region. With pharmaceutical sales of more than $64bn, it is an attractive market for pharma, however it is also one in which each market differs in terms of opportunities and challenges.
Immuno-oncology: The market opportunity for PD-1/PD-L1s
Immuno-oncology is the new frontier in cancer treatment. Using the body’s own immune system to treat cancer, new therapies are producing impressive survival benefits, with reduced side effects. Of these therapies, immune checkpoint inhibitors are showing particular promise. Our latest infographic is a snapshot of the PD-1/PD-L1 market at this time.
Conference Live infographic
Conference Live gives you real-time insights, utilising the multimedia functionality of the smartphone in an innovative mobile app methodology. We conduct mobile conference research amongst physicians attending conferences, giving our clients real-time feedback and insight into delegates’ reactions as they happen. Our approach is very successful at engaging respondents, offers rich insights and immediate outputs.
HIV Market Snapshot infographic
Our latest HIV infographic, taken from data collected from syndicated tracking study Therapy Watch, reveals that more than 3 in 5 naive or switch patients are currently treated with a STR (single tablet regimen), which has a clear impact on their quality of life. Therapy Watch HIV patient data is collected bi-monthly from a panel of 150 physicians across the main 5 EU markets and 100 physicians in the US.